Dr. DeKernion is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10833 Le Conte Ave.
Los Angeles, CA 90095Phone+1 310-794-7700
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Urology, 1972 - 1973- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Surgery, 1969 - 1972
- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Surgery, 1965 - 1967
Louisiana State University School of Medicine in New OrleansClass of 1965
Certifications & Licensure
CA State Medical License 1973 - 2020- American Board of Surgery Surgery
- American Board of Urology Urology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
- Fellow (FACS) American College of Surgeons
Publications & Presentations
PubMed
- 785 citationsUse of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease: A Prospective Multicenter Clinical...William J. Catalona, Alan W. Partin, Kevin M. Slawin, Michael K. Brawer, Robert C. Flanigan
JAMA. 1998-05-20 - 68 citationsComparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,63...William J Catalona, Jerome P Richie, Frederick R Ahmann, M'Liss A Hudson, Peter T Scardino
The Journal of Urology. 2017-02-01 - 497 citationsRisk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell CarcinomaAmnon Zisman, Allan J. Pantuck, Jeffery Wieder, Debby H. Chao, Fredrick Dorey
Journal of Clinical Oncology. 2002-12-01
Press Mentions
Trethera Receives $2 Million National Cancer Institute Grant for Advancement of Clinically Relevant Biomarkers in Phase 1 TrialMay 31st, 2023
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
